Pfizer kept its sales forecast for its antiviral treatment Paxlovid and its COVID-19 vaccine below analysts’ estimates as demand slows.
(Reuters) – Pfizer on Tuesday kept its annual sales forecast for its antiviral treatment, Paxlovid, and its COVID-19 vaccine below analysts’ estimates, as demand slows.
The American pharmaceutical company said it expected sales of Paxlovid to reach $22 billion this year, while analysts had expected an average of $26.1 billion.
He also reiterated his forecast of $32 billion in sales for the COVID-19 vaccine it developed with BioNTech.
At the request of the Securities and Exchange Commission, the US federal market regulator, several pharmaceutical companies have adjusted their forecasts to include spending related to milestone payments and acquisitions.
Pfizer has therefore lowered its annual adjusted earnings target to $6.25-6.45 (5.95-6.14 euros) per share for the full year, from a previous forecast of 6 .35 to $6.55, mainly due to the impact of these expenses.
(Report Manas Mishra in Bangalore, French version Augustin Turpin, edited by Kate Entringer)
Copyright © 2022 Thomson Reuters